alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 17,601–17,625 of 27,146 studies marked Peer-reviewed (page 705 of 1086) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Serum insulin-like growth factor-I and amyloid beta protein in Alzheimer's disease: relationship with cognitive function

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society 2015-10-06

The results, specifically that lower serum IGF-I was associated with cognitive impairment, suggest that metabolism of IGF-I may be involved in the pathogenesis of cognitive deficits in Alzheimer's disease. 4 key findings →

Participants: 81 Evidence: low

Full summary, score breakdown and related studies → Original source

Serum NGAL is Associated with Distinct Plasma Amyloid-β Peptides According to the Clinical Diagnosis of Dementia in Down Syndrome

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Alzheimer's disease : JAD 2015-01-01

Serum NGAL levels are increased in DS and associated with distinct species of Aβ depending on the progression of dementia as diagnosed by baseline and follow-up clinical assessments. 5 key findings →

Participants: 67 Evidence: low

Full summary, score breakdown and related studies → Original source

Intracellular Amyloid-β in the Normal Rat Brain and Human Subjects and Its relevance for Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Alzheimer's disease : JAD 2023-01-01

Expression of iAβ42 in healthy Wistar rats predominates in the same structures where iAβ accumulates and Aβ plaques initially form in the much used, Wistar based McGill-R-Thy1-APP rat model for AD. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Reactive Astrocytes Contribute to Alzheimer's Disease-Related Neurotoxicity and Synaptotoxicity in a Neuron-Astrocyte Co-culture Assay

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in cellular neuroscience 2022-01-21

Pathogenesis of presymptomatic disease stages remains elusive, although studies suggest that the early structural and functional alterations likely occur at neuronal dendritic spines. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Two novel presenilin-1 mutations (I249L and P433S) in early onset Chinese Alzheimer's pedigrees and their functional characterization

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Biochemical and biophysical research communications 2019-06-21

Clinical case study and functional characterization of the disease-associated presenilin-1 (PSEN1) mutations may help reveal the roles of PSEN1 in the pathogenesis of Alzheimer's disease (AD). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Correlation of serum complement factor 5a level with inflammatory response and cognitive function in patients with Alzheimer's disease of different severity

✓ Peer-reviewed alzhub usefulness score 43 out of 100. BMC neurology 2023-09-07

Serum C5a level increased with AD severity, and its expression was positively correlated with serum pro-inflammatory factor levels, and negatively correlated with cognitive function. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

A Novel PSEN1 K311R Mutation Discovered in Chinese Families with Late-Onset Alzheimer's Disease Affects Amyloid-β Production and Tau Phosphorylation

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Alzheimer's disease : JAD 2017-01-01

The K311R mutation might contribute to AD pathogenesis by overproducing toxic Aβ species and enhancing tau phosphorylation. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Diagnostic utility of VEGF and soluble CD40L levels in serum of Alzheimer's patients

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Clinica chimica acta; international journal of clinical chemistry 2015-12-17

We identified the feasibility of a blood-based biomarker approach in AD diagnostics though the results warrant validation in large-scale studies. 3 key findings →

Participants: 90 Evidence: low

Full summary, score breakdown and related studies → Original source

Preparedness of China's health care system to provide access to a disease-modifying Alzheimer's treatment

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2023-06-06

Closing this gap will require the introduction of high-performing blood tests, greater reliance on cerebrospinal fluid (CSF) testing, and expansion of positron emission tomography (PET) capacity. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Slowly progressive behavioral frontotemporal dementia with C9orf72 mutation. Case report and review of the literature

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Neurocase 2018-01-22

We present a 86-year-old woman without relevant medical history and two brothers who died by dementia, who started at 55 years with depression and personality changes with ongoing worsening (>30 years) and functional decline. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Revised Criteria for Diagnosis and Staging of Alzheimer's Disease: Alzheimer's Association Workgroup

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Alzheimer's & Dementia 2024-06-27

This Alzheimer's Association workgroup paper proposes a major update to how Alzheimer's disease is diagnosed: it defines the disease by biological markers (amyloid plaques and tau tangles detected via blood, CSF, or PET) rather than requiring clinical symptoms like memory loss to be present. 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source

FDA approval of the Lumipulse G pTau217/β-amyloid 1-42 plasma ratio test: a new era in accessible Alzheimer's diagnosis

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Annals of Medicine and Surgery 2025-12-17

This review article discusses the FDA's May 2025 clearance of Fujirebio's Lumipulse G blood test, the first FDA-cleared blood test for aiding Alzheimer's diagnosis (via the pTau217/beta-amyloid 1-42 ratio). 4 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source

GUIDE and Beyond: Strategies for Comprehensive Dementia Care Integration

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Journal of the American Geriatrics Society 2025-11

Written by leaders of six established comprehensive dementia-care programs (including Care Ecosystem, MIND at Home, and BRI Care Consultation) that helped shape the CMS GUIDE model, this paper lays out a practical four-step roadmap for organizations trying to launch or sustain comprehensive dementia care programs like GUIDE. 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Alzheimer's & Dementia 2018-04

This influential 2018 paper proposed defining Alzheimer's disease by what is happening biologically in the brain (amyloid plaques, tau tangles, and neuron loss, measured by scans or spinal fluid tests) instead of by memory symptoms alone. 4 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source

Blots on a field?

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Science 2022-07-21

Science journalist Charles Piller, working with neuroscientist Matthew Schrag and independent image-forensics experts, published a six-month investigation finding apparent digital manipulation (duplicated bands, spliced images) in Western blot figures from papers by Sylvain Lesné, including his highly influential 2006 Nature paper proposing that a specific amyloid protein (Aβ*56) causes memory loss. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source

Caspase-1 inhibition improves cognition without significantly altering amyloid and inflammation in aged Alzheimer disease mice

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Cell death & disease 2022-10-11

Human genetic and animal model studies indicate that brain microglial inflammation is a primary driver of cognitive impairment in Alzheimer Disease (AD). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed